Improving social functioning and reducing psychosis risk through cognitive training
Targeting Processing Speed Deficits to Improve Social Functioning and Lower Psychosis Risk in Adolescents at Clinical High Risk for Psychosis
This study is testing a 10-week program to see if cognitive training can help teenagers at risk for psychosis improve their thinking skills and social interactions.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 54 (estimated) |
| Ages | 14 Years to 20 Years |
| Sex | All |
| Sponsor | Northwell Health Academic / other |
| Locations | 1 site (Glen Oaks, New York) |
| Trial ID | NCT05131035 on ClinicalTrials.gov |
What this trial studies
This intervention focuses on enhancing processing speed in adolescents at clinical high risk for psychosis through a program called SCORES (Specific Cognitive Remediation with Support). Over 10 weeks, participants engage in cognitive training exercises and receive group support to improve their cognitive abilities and social skills. The study aims to evaluate the effectiveness of this approach in reducing symptoms associated with psychosis and improving overall social functioning. The intervention includes performance-based rewards and game-like tasks to boost motivation and engagement.
Who should consider this trial
Good fit: Ideal candidates are adolescents who meet Clinical High Risk criteria for psychosis and exhibit specific cognitive deficits.
Not a fit: Patients with a diagnosed schizophrenia-spectrum disorder or significant cognitive impairments may not benefit from this intervention.
Why it matters
Potential benefit: If successful, this intervention could significantly improve social functioning and reduce the risk of developing psychosis in at-risk adolescents.
How similar studies have performed: Other studies have shown promise in using cognitive remediation approaches to improve outcomes in similar populations, suggesting potential for success in this novel intervention.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Meet Clinical High Risk (CHR) criteria on the Structured Interview for Psychosis Risk Syndromes, defined by the presence of at least one attenuated positive symptom at a moderate to severe level * A score representing 0.5 SD below the mean on Animal Naming, Trails A or BACS: Symbol Coding from the MATRICS Consensus Cognitive Battery (MCCB). Exclusion Criteria: * Any DSM 5 Schizophrenia-Spectrum diagnosis * Non-English speaking * Past or current history of a clinically significant central nervous system disorder (e.g., seizure disorder) * Estimated IQ\<70 * Significant head injury * Significant substance abuse * Significant visual or auditory impairment.
Where this trial is running
Glen Oaks, New York
- Northwell Health- The Zucker Hillside Hospital — Glen Oaks, New York, United States (Recruiting)
Study contacts
- Principal investigator: Ricardo E Carrion, Ph.D. — Northwell Health
- Study coordinator: Ricardo E Carrion, Ph.D.
- Email: rcarrion@northwell.edu
- Phone: 718-470-8788
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.